161 related articles for article (PubMed ID: 12362279)
1. New drugs, old drugs - dear drugs, cheap drugs.
Hirschel B; Garbino J
Swiss Med Wkly; 2002 Jun; 132(23-24):301-2. PubMed ID: 12362279
[No Abstract] [Full Text] [Related]
2. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
3. Comment: caspofungin acetate for treatment of invasive fungal infections.
Chan J
Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical therapy.
Marty FM; Lowry CM
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
[No Abstract] [Full Text] [Related]
6. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
7. [New antifungal agents and bronchopulmonary mycoses].
Germaud P; Morin O
Rev Pneumol Clin; 2004 Jun; 60(3):139-44. PubMed ID: 15292822
[TBL] [Abstract][Full Text] [Related]
8. New antifungal drugs and new clinical trials: interpreting results may be difficult.
Girmenia C; Martino P
Curr Opin Oncol; 2003 Jul; 15(4):283-8. PubMed ID: 12874505
[TBL] [Abstract][Full Text] [Related]
9. [Systemic antifungal agents].
Lumbreras C; Lizasoain M; Aguado JM
Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
[TBL] [Abstract][Full Text] [Related]
10. Update on antifungal therapy.
Gigolashvili T
Cancer Pract; 1999; 7(3):157-9. PubMed ID: 10352080
[No Abstract] [Full Text] [Related]
11. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
Colombo GL; Morlotti L; Serra G
Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant.
Castagnola E; Machetti M; Cappelli B; Molinari AC; Morreale G; Dodero P; Tomà P; Faraci M
Clin Microbiol Infect; 2004 Mar; 10(3):255-7. PubMed ID: 15008948
[TBL] [Abstract][Full Text] [Related]
14. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
16. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.
Kulemann V; Bauer M; Graninger W; Joukhadar C
Pharmacology; 2005 Dec; 75(4):165-78. PubMed ID: 16192747
[TBL] [Abstract][Full Text] [Related]
17. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
Schäfer-Korting M
Mycoses; 2003; 46 Suppl 1():28-31. PubMed ID: 12955850
[TBL] [Abstract][Full Text] [Related]
18. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with caspofungin and amphotericin B lipid complex.
Lum LR; Turco TF; Leone J
Am J Health Syst Pharm; 2002 Jan; 59(1):80-1. PubMed ID: 11813474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
